Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 20/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 18/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7660526 | 1.00 | CCR3 (0.82) | CCR3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL7662477 | 0.94 | CCR3 (0.84) | CCR3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL6780897 | 0.90 | CCR3 (0.88) | CCR3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL6773441 | 0.90 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL6774223 | 0.89 | CCR3 (0.86) | CCR3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL6773087 | 0.89 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL7663873 | 0.88 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL6770360 | 0.88 | CCR3 (0.86) | CCR3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL18844267 | 0.86 | CCR3 (0.95) | CCR3SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL7666626 | 0.85 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | claimed |
| US-6706735-B2 | NITROGEN COMPOUNDS SUCH AS N-(3-(4-BENZYL-2-PIPERIDINYL)PROPYL )-N'-(3-CYANOPHENYL)UREA, USED AS CHEMOTACTIC CYTOKINE CONTROLLERS ADMINISTERED FOR PROPHYLAXIS OF ASTHMA, ALLERGIES AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | disclosed |